Clinical trial of ganglioside combined with mouse nerve growth factor on serum markers of nerve injury in the treatment of children with premature brain injury
10.13699/j.cnki.1001-6821.2018.05.011
- VernacularTitle:神经节苷脂联合鼠神经生长因子对早产儿脑损伤后血清神经损伤标志物的影响
- Author:
Lei ZHOU
1
;
Yong CAI
;
Shao-Zhen LIANG
;
Yuan-Qing LIN
Author Information
1. 广州医科大学 附属第三医院 儿科
- Keywords:
ganglioside;
mouse nerve growth factor;
premature brain injury;
nerve injury marker
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(5):524-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of ganglioside combined with mouse nerve growth factor in the treatment of children with premature brain injury on serum markers of nerve injury.Methods A total of 78 infants of gestational aged ＜ 37 weeks with brain injury were randomly divided into treatment group and control group,39 cases in each group.The control group was treated with citicoline injection 0.125 g,qd,intravenous drip.On the basis of control group,treatment group was treated with monosialotetrahexosyl ganglioside sodium injection 20 mg,qd +mouse nerve growth factor injection 18 μg,qd,intravenous drip.The children in two groups were treated for 14 d.Blood samples were collected within 24 h and 14 d after birth to determine the levels of myelin basic protein(MBP),S-100β protein,tumor necrosis factor-α(TNF-α),interleukin-6 (IL-6),Toll-like receptor-4 (TLR-4)in two groups.The clinical effect and adverse drug reactions were also compared in two groups.Results After treatment,the total improvement rates of treatment group and control group were 94.87％ (37 cases/39 cases),76.92％ (30 cases/39 cases),with significant difference (P ＜0.05).After treatment,the levels of serum MBP in treatment group and control group were (2.01 ± 0.58) and (2.46 ± 0.67)μg · L-1,S-100β levels were (0.69 ± 0.28) and (0.91 ± 0.35) μg · L-1,TNF-α were (2.04 ± 1.03) and (3.15 ± 1.26) μg · L-1,IL-6 levels were (161.78 ±44.18) and (257.63 ±51.36) ng · L-1,TLR-4 levels were (8.45 ± 4.37) and (11.68 ± 4.94) pg · mL-1,the consciousness recovery time were (2.30 ± 0.57) and (3.21 ±0.64)d,the recovery time of sucking ability were(4.17 ±0.42)and(5.01 ±0.45)d,primary reflex recovery time were (4.23 ± 0.48) and (6.85 ± 0.59) d,recovery time of muscle tension were (4.68 ± 0.49) and (7.04 ±0.53)d,with significant di-fference (P ＜0.05).The adverse drug reactions were gastrointestinal reaction and fever in treatment group,the drug adverse reactions were gastrointestinal reaction,agitation and fever in control group.The incidence of adverse drug reactions of treatment group and control group were 10.26％ (4 cases/39 cases),12.82％ (5 cases/39 cases),with no significant difference (P ＞ 0.05).Conclusion Ganglioside combined with mouse nerve growth factor is effective in the treatment of preterm infants with brain injury,and shorten the recovery time,improve the nerve function,with high safety.
